There are currently 1342 clinical trials in Columbus, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Nationwide Children's Hospital, Ohio State University Comprehensive Cancer Center, Ohio State University and The Ohio State University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
NCT05934526
Recruiting
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Pulmonary Arterial Hypertension
Register for Updates
Intratumoral PH-762 for Cutaneous Carcinoma
NCT06014086
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Centricity Research, Columbus, Ohio
Conditions: Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
Register for Updates
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
NCT03496883
Recruiting
The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (m... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/10/2024
Locations: OSU Wexner Medical Center, Columbus, Ohio +1 locations
Conditions: Intracerebral Hemorrhage
Register for Updates
Add-on Reparixin in Adult Patients With ARDS
NCT05496868
Recruiting
Study objectives To characterize the efficacy of reparixin in ameliorating lung injury and systemic inflammation and expediting clinical recovery and liberation from mechanical ventilation in adult patients with moderate to severe ARDS (PaO2/FIO2 ratio ≤ 200). To evaluate the safety of reparixin vs. placebo in patients enrolled in the study.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Acute Respiratory Distress Syndrome, Adult
Register for Updates
Transcutaneous Sensors for the Detection of Cancer-Related Lymphedema, Project Limb Rescue Study
NCT06305884
Recruiting
This clinical trial studies how well new adhesive-based sensors that stick to the skin (transcutaneous) work in detecting cancer-related long-term arm swelling (lymphedema). For many patients, lymphedema s painful, unsightly, and weakening. The early signs of lymphedema are hard to see, and sometimes it is only diagnosed by hospital equipment at larger centers. Treating lymphedema early is usually more successful than trying to treat in later stages. The adhesive-based sensors used in this study... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
06/10/2024
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Hematopoietic and Lymphoid System Neoplasm, Lymphedema, Malignant Solid Neoplasm
Register for Updates
Phase III Study of AK112 for NSCLC Patients
NCT06396065
Recruiting
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Zangmeister Cancer Center, Columbus, Ohio
Conditions: Non-Squamous Non-small Cell Lung Cancer
Register for Updates
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
NCT03735667
Recruiting
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
Gender:
All
Ages:
All
Trial Updated:
06/10/2024
Locations: Mount Carmel Columbus Cardiology Consultants, Columbus, Ohio +1 locations
Conditions: Aortic Stenosis
Register for Updates
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
NCT03876769
Recruiting
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, and survival. After tisagenlecleucel infusion, patient will have assessments performed more frequently in the first month and then at Day 29, then every 3 months f... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
06/10/2024
Locations: Nationwide Childrens Hospital suite T6B, Columbus, Ohio
Conditions: B-Cell Acute Lymphoblastic Leukemia
Register for Updates
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
NCT05213624
Recruiting
This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study. Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Kidney Disease, Chronic
Register for Updates
A Study to Investigate LYL845 in Adults With Solid Tumors
NCT05573035
Recruiting
This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
Register for Updates
A Study of Felzartamab in Participants With Lupus Nephritis
NCT06064929
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of felzartamab plus standard of care in participants with refractory Lupus Nephritis (LN).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: HI-Bio Investigational Site, Columbus, Ohio
Conditions: Lupus Nephritis
Register for Updates
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
NCT06410924
Recruiting
This is a Phase 2 Study to evaluate the effect of DD01 treatment in overweight/obese patients with metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/10/2024
Locations: Summit Research Site, Columbus, Ohio
Conditions: NAFLD, NASH
Register for Updates